NCT03987152 · CITED IN SOURCE DOCUMENTS

Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE3
Status at capture: UNKNOWN
Registry last update: 2021-01-29

Congenital vascular anomalies are uncommon and belong to the group of rare diseases.These vascular malformations can cause serious complications including obstruction of vital organs and their function, recurrent infection and significantly reduced quality of life of persons affected.Treatment options range from conservative to surgical extirpation or intralesional embolisation/sclerosis. Unfortunately, this is often not enough. Many patients still have complaints like severe pain and invalidation due to the lymphatic or venous malformation making a normal functional life impossible. Recent case reports mention the positive effects of refractory patients with Sirolimus. Sirolimus, also known as rapamycin, is currently the only FDA-approved mammalian target of rapamycin (mTOR) inhibitor.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: Inclusion Criteria: * Diagnosis of Congenital venous malformation, or lymphatic malformation or combined. * Age older than 1 yr. * Patients (or legal guardians for children) have to be able to sign the informed consent * Patients are either refractory to standard care such as medical treatment (low molecular weight heparins, pain medication etc.), surgical resection and/or sclerotherapy/embolization (ineffective or accompanied by major complications) or there is no possibility for surgical intervention anymore. Only patients that have a normal clinical screening (no signs for infection, normal bone marrow function, normal liver and kidney function, normal glucose metabolism etc.) can be included. * Patients included have no cardiac impairment * Patients have no gastrointestinal impairment as Sirolimus is absorbed gastro-intestinal and normal function is needed * No other underlying medical disorder like Down syndrome or other syndromes * Women of reproductive age have to be informed that contraceptive methods are * mandatory during the study time, pregnant women are excluded * Karnofsky score \> 50 Exclusion Criteria: * No written informed consent * Known hypersensitivity to drugs or metabolites from similar classes as study treatment. * Patient has other concurrent severe and /or uncontrolled medical condition that would, in the investigator's judgment, contraindicated participation in the clinical study (e.g. acute or chronic pancreatitis, liver cirrhosis, active chronic hepatitis, severely impaired lung function with a spirometry ≤ 50% of the normal predicted value and/or O2 saturation ≤ 88% at rest, etc.) * Recent history of primary malignancy ≤ 5 years * Impaired cardiac function or clinically significant cardiac diseases * Immunocompromised patients, including known seropositivity for HIV * Patient with any other concurrent severe and /or uncontrolled medical condition that would,in the investigator's judgment, contraindicated participation in the clinical study. * Pregnant or lactating women * Karnofsky score \< 50
healthy Volunteers: false
minimum Age: 1 Year
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Sirolimus administration: during Challenge and Rechallenge phase. Compared with the period 2 months before start of Sirolimus.
intervention Names
Drug: Sirolimus
label
Sirolimus
type
OTHER

interventions

arm Group Labels
Sirolimus
description
Daily intake of Sirolimus during Challenge and Rechallenge phase
name
Sirolimus
other Names
No other treatment
type
DRUG

Study design

allocation

intervention Model

SEQUENTIAL

intervention Model Description

Challenge-Dechallenge-Rechallenge design All patients receive Sirolimus during challenge phase (6 months), stop Sirolimus during dechallenge phase (12 months), and if pain/symptoms returns Sirolimus intake is restarted during the rechallenge phase.

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 75
type: ESTIMATED

Registered outcome plans (not posted results)

primary Outcomes

description
Quality of life: Questionnaire for Preschool Children's Health-Related Quality of Life (TAPQOL). Preschool Children Quality of Life, parent-reported questionnaire clustered into 12 multi-item scales, with higher scores range 0-100) indicating better HRQOL)
measure
Quality of life using Sirolimus measured with survey (TAPQOL)
time Frame
Change from baseline Quality of life at 6 months QoL in challenge phase, and 12 months QoL in Rechallenge phase.
description
Quality of life: Pediatric Quality of Life Inventory (PedsQl) (children) 23 items questionnaire, 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). Psychosocial Health Summary Score, Physical Health Summary Score and Total score will be measured.
measure
Quality of life using Sirolimus measured with survey (PedsQl)
time Frame
Change from baseline Quality of life at 6 months QoL in challenge phase, and 12 months QoL in Rechallenge phase.
description
Quality of life: Rand-36 (adults) eight health domains; physical functioning, social functioning, role limitations due to physical health problems, role limitations due to emotional problems, mental health, vitality, pain and general health perception. Outcomes at each domain will be defined on a scale from a minimum score of 0 to a maximum score of 100. A higher score is equivalent to a better health.
measure
Quality of life using Sirolimus measured with survey (Research and development Rand-36).
time Frame
hange from baseline Quality of life at 6 months QoL in challenge phase, and 12 months QoL in Rechallenge phase
description
Daily pain score (daily visual analogue scale (VAS-score 0-10) for children, and numeric rating scale (NRS-score 0-10) for adults)
measure
Difference in pain scores after using Sirolimus measured with VAS score
time Frame
Daily pain scores will be compared after 6 months in Challenge phase, after Challenge phase: starts the phase, and pain during 12 months in the Rechallenge phase
description
Daily pain score (daily numeric rating scale (NRS-score 0 no pain -10 extreme pain) for adults)
measure
Difference in pain scores after using Sirolimus measured with NRS score
time Frame
Daily pain scores will be compared after 6 months in Challenge phase, after Challenge phase: starts the phase without Sirolimus treatment, and pain during 12 months in the Rechallenge phase

secondary Outcomes

description
Amount of patients who have lowered pain or are pain free. Duration of lowered pain or pain free period in days.
measure
Return of pain after treatment and duration of lowered pain or pain free period in days
time Frame
After 6 months Sirolimus intake till one year follow up.
description
MRI of the vascular malformation will be made at the beginning of the study and after six months of treatment with Sirolimus. An experienced radiologist will evaluate the evolution of the volume of the malformation.
measure
Growth/progression of vascular malformation
time Frame
MRI baseline compared with MRI after 6 months in challenge phase and 12 months in rechallenge phase
description
Adverse events: short and long term consequences of treatment with Sirolimus according to CTCAE version 5.0.
measure
Rate and occurence of adverse events related to Sirolimus
time Frame
4 years
description
Adverse events: short and long term consequences of treatment with Sirolimus according to CTCAE version 5.0.
measure
Severity of adverse events related to Sirolimus
time Frame
4 years
description
Secondary material that was obtained after surgery, stored in the HECOVAN biobank can be used for analyses. Comprehensive targeted Next Generation Sequencing screen using Unique Molecular Identifiers with a technical sensitivity of 1% mutant alleles was performed for frequently mutated positions using Single Molecule Molecular Inversion Probes. We will investigate if there is a correlation with a possible found mutation and painreduction or improvement of quality of life.
measure
Genetic mutations in the vascular malformation that can predict outcome of treatment with Sirolimus using Single Molecule Molecular Inversion Probes (smMIPs)
time Frame
4 years
description
Genotyping will be performed using Taqman assays or Kompetitive Allele Specific PCR (KASPTM) assays in saliva swabs. Pharmacogenetic profiles (slow, intermediate, and extensive metabolizer) will be determined. Subjects compared on the outcome of sirolimus effectiveness for pain, and QoL stratified by CYP3A4.
measure
Pharmacogenetic profile in the vascular malformation that can predict outcome of treatment with Sirolimus
time Frame
4 years
description
Via standardized questionnaires developed by the iMTA (institute for Medical Technology Assessment). The second part of the cost analysis consists of determining the cost prices for each volume of consumption.
measure
Cost-effectiveness of administration of Sirolimus: Quality Adjusted Life Year (QALY) estimate for each patient
time Frame
4 years

Full study description

brief Summary: Congenital vascular anomalies are uncommon and belong to the group of rare diseases.These vascular malformations can cause serious complications including obstruction of vital organs and their function, recurrent infection and significantly reduced quality of life of persons affected.Treatment options range from conservative to surgical extirpation or intralesional embolisation/sclerosis. Unfortunately, this is often not enough. Many patients still have complaints like severe pain and invalidation due to the lymphatic or venous malformation making a normal functional life impossible. Recent case reports mention the positive effects of refractory patients with Sirolimus. Sirolimus, also known as rapamycin, is currently the only FDA-approved mammalian target of rapamycin (mTOR) inhibitor.
detailed Description: Congenital vascular anomalies are uncommon and belong to the group of rare diseases. In 1996, the International Society of the Study of Vascular Anomalies adopted a new classification, distinguishing vascular malformations from vascular tumors. This classification was revised in 2014 and newly identified genetic features were taken into account. Vascular malformations feature dysplastic malformed vessels and are a consequence of a defective development of the embryonic vascular system. Vascular malformations can involve lymphatic vessels, capillaries, veins and arteries or even combinations. These vascular malformations are present at birth and grow with the child. Treatment options range from conservative to surgical extirpation or intralesional embolisation/sclerosis. Unfortunately, this is often not enough. Many patients still have complaints like severe pain and invalidation due to the lymphatic or venous malformation making a normal functional life impossible. These vascular malformations can cause serious complications including obstruction of vital organs and their function, recurrent infection and significantly reduced quality of life of persons affected. As the natural course of the disease affects multiple body systems, the therapeutic management is challenging. To date, no other medical treatment options are available. Although standard pain medication is given according the (inter) national pain protocols, patients still suffer pain and are not able to function normally in daily life. Majority (60-70% percent of the patients) of the patients is not able to have a normal life, with a normal job and normal social activities. Children are often not able to go to school normally, cannot play outside and have pain at the site of the malformation. The vast majority of literature reporting medical therapies for vascular anomalies consists of case reports and small series and is complicated by publication bias (negative findings are often not published), inconsistent use of nomenclature, and the absence of clinical trials. Recent case reports mention the positive effects of refractory patients with Sirolimus. Sirolimus, also known as rapamycin, is currently the only FDA-approved mammalian target of rapamycin (mTOR) inhibitor, indicated for prevention of kidney allograft rejection in adults and children 13 years or older, but is commonly used to manage organ rejection in younger children.

Source references

references

citation
Harbers VEM, Bouwman FCM, van Rijnsoever IMP, Verhoeven BH, van der Vleuten CJM, Schultze Kool LJ, de Laat PCJ, van der Horst CMAM, Kievit W, Te Loo DMWM. Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus. Front Med (Lausanne). 2023 Apr 20;10:1155476. doi: 10.3389/fmed.2023.1155476. eCollection 2023.
pmid
37153086
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-24d24903fe4524ed8fd9
requested nct id
NCT03987152
primary nct id
NCT03987152
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-vascular-tumors-treatment-pdq
source record id
Source null
source file sha256
640d3ee58359f60bbc6b909aaea267a52acd5f54a36548b1b9164a865209b1e3
payload sha256
73a60977e73bc52eee2b1979774606874185c0a4fe3ca26f3084a165a706dc71
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-24d24903fe4524ed8fd9
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT03987152
occurrences
context exact
atment with sirolimus. Phase III clinical trials are underway in Europe (e.g., <a href="/clinicaltrials/NCT02638389">NCT02638389</a>, <a href="/clinicaltrials/NCT03987152">NCT03987152</a>, and <a href="/clinicaltrials/NCT04980872">NCT04980872</a>). A 2018 study reported promising level C evidence for the use of the PI3K inhibit
end
21713
exact text
NCT03987152
start
21702
context exact
irolimus. Phase III clinical trials are underway in Europe (e.g., <a href="/clinicaltrials/NCT02638389">NCT02638389</a>, <a href="/clinicaltrials/NCT03987152">NCT03987152</a>, and <a href="/clinicaltrials/NCT04980872">NCT04980872</a>). A 2018 study reported promising level C evidence for the use of the PI3K inhibitor BYL719 (al
end
21726
exact text
NCT03987152
start
21715
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/11b7dc23ff39b4d707.html
source file sha256
640d3ee58359f60bbc6b909aaea267a52acd5f54a36548b1b9164a865209b1e3
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:22:19.675923+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
731dd14843bcb9b23d2be557f0e8f877711428ea4eaf76a0a36a2af22f9919b5
source title
Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: April 17, 2025
datetime
2025-04-17T12:00:00Z
display
April 17, 2025
source url
https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-vascular-tumors-treatment-pdq

Preserved source evidence · Not medical advice